The groundbreaking success of Sildenafil undeniably transformed the medication landscape, but placing funds in companies strongly reliant on generic versions presents a complex picture. While early profits were significant, the end of patents and the rise of cheaper alternatives have weakened market share. Therefore, a thorough evaluation of ongoin